2 Results Sort by:
Membrane-anchored Fusokine as Vaccine Adjuvant to Prevent Viral Infection
Application GIFT4 anchored to virus-like particles (VLPs) as a prophylactic vaccine adjuvant to prevent chronic viral infections including HIV, HBV, HPV and influenza. Key Benefits GIFT4-containing VLPs induce higher antibody response than non-adjuvanted VLPs. Effectively induce strong mucosal immune response. Market Summary Currently, there...
Published: 4/23/2024       Contributor(s): Baozhong Wang, Richard Compans, Jacques Galipeau, Jiusheng Deng
Novel Vaccine Antigen Presentation Platforms
Application Combined antigen-adjuvant virus-like particle (VLP) vaccine platform for enhanced immune response. Key Benefits Chimeric VLPs (cVLPs) contain both antigen and adjuvant, thereby enhancing both cellular and humoral responses. cVLPs are safer than live replicating vectored vaccines because of their lack of infectivity. The cVLP manufacturing...
Published: 7/28/2023       Contributor(s): Baozhong Wang, Fu Shi Quan, Martin Moore, Richard Compans, Alan Aderem, Ioanna Skountzou, Jadranka Bozja